CAMBRIDGE, Mass., April 17, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage
biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare
neuromuscular diseases, will report first quarter 2017 financial results after the Nasdaq Global Market closes on Thursday, April
27, 2017. Subsequently, at 4:30 p.m., Eastern Time, Edward Kaye, M.D., Sarepta’s chief executive officer, Sandy Mahatme, Sarepta’s
chief financial officer and chief business officer, and Bo Cumbo, Sarepta’s head of global commercial will host a conference call
to discuss first quarter 2017 financial results and to provide a corporate update.
The conference call may be accessed by dialing 574-990-1451 for domestic callers and 1-844-534-7313 for international callers.
The passcode for the call is 9321329. Please specify to the operator that you would like to join the "Sarepta First Quarter 2017
Earnings Call." The conference call, along with a slide presentation, will be webcast live under the investor relations section of
Sarepta's website at www.sarepta.com and will be archived there following the call for 90 days. Please connect to
Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be
necessary.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of unique
RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing
the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information,
please visit us at www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website
at www.sarepta.com. We encourage investors and potential investors to consult our website regularly
for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors: Sarepta Therapeutics, Inc. Ian Estepan, 617-274-4052 iestepan@sarepta.com or W2O Group Brian Reid, 212-257-6725 breid@w2ogroup.com
